Immune Tolerance Network (UM1 Clinical Trial Required)
AGENCY
HHS-NIH11
PROGRAM
Discretionary
AMOUNT
—
CLOSES
Jan 29, 2027
Description
The purpose of this notice of funding opportunity (NOFO) is to support applications to continue the Immune Tolerance Network (ITN). The primary objective of the Network is to develop tolerogenic therapies for immune-mediated disorders. The three main clinical areas of work are: 1) Allergic diseases and asthma; 2) Autoimmune diseases; and 3) Immune-mediated consequences of transplantation. The core functions of the ITN include designing, conducting, and sharing the results of clinical trials and performing integrated mechanistic studies.
Eligibility
Special district governments; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Private institutions of higher education; Others (see text field entitled "Additional Information on Eligibility" for clarification); Small businesses; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; County governments; Independent school districts; City or township governments; Public and State controlled institutions of higher education; Native American tribal governments (Federally recognized); For profit organizations other than small businesses; Native American tribal organizations (other than Federally recognized tribal governments); Public housing authorities/Indian housing authorities; State governments
Contact
Additional details
- Funding instrument
- Cooperative Agreement
- Cost sharing required
- No
- Archived
- Mar 29, 2027
Opportunity number: RFA-AI-28-005
Search this number on Grants.gov for the official listing.